Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

医学 析因分析 超重 2型糖尿病 肥胖 糖尿病 内科学 内分泌学
作者
Emily R. Hankosky,Hui Wang,Lisa M. Neff,Hong Kan,Fangyu Wang,Nadia N. Ahmad,Adam Stefański,W. Timothy Garvey
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (12): 3748-3756 被引量:16
标识
DOI:10.1111/dom.15269
摘要

Abstract Aim We assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT‐1 trial. Materials and Methods In this post hoc analysis of SURMOUNT‐1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10‐year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo. Mean changes in risk scores from baseline to weeks 24 and 72 were compared between tirzepatide and placebo groups. Subgroup analyses were conducted based on participants' glycaemic status and body mass index at baseline. Results Mean baseline T2D predicted risk scores did not differ between tirzepatide and placebo groups (range: 22.9%‐24.3%). At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%). At week 72, median relative predicted risk reductions following tirzepatide treatment ranged from 60.3% to 69.0%. For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo. At week 72, participants with prediabetes (range: 16.0%‐20.3%) had greater mean risk score reductions from baseline versus those without prediabetes (range: 10.1%‐11.3%). Across body mass index subgroups, mean reductions from baseline were significantly greater in tirzepatide groups versus placebo. Conclusion Tirzepatide treatment significantly reduced the 10‐year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官发布了新的文献求助10
刚刚
刚刚
刚刚
不会吹口哨完成签到,获得积分10
1秒前
钙离子发布了新的文献求助10
1秒前
英俊的铭应助澡雪采纳,获得10
3秒前
稗子发布了新的文献求助10
4秒前
HeJiangle发布了新的文献求助10
4秒前
顾矜应助默默书竹采纳,获得10
6秒前
比巴卜发布了新的文献求助10
6秒前
CC发布了新的文献求助10
7秒前
夕夕口口完成签到,获得积分10
7秒前
1111应助AHA采纳,获得20
9秒前
牛虻发布了新的文献求助10
12秒前
orixero应助山语采纳,获得10
12秒前
12秒前
Master完成签到 ,获得积分10
13秒前
13秒前
月儿完成签到 ,获得积分10
14秒前
1177发布了新的文献求助10
14秒前
勤奋凝安完成签到,获得积分20
14秒前
量子星尘发布了新的文献求助10
16秒前
16秒前
17秒前
18秒前
auggy发布了新的文献求助10
18秒前
18秒前
默默书竹发布了新的文献求助10
18秒前
21秒前
英俊的铭应助Picky采纳,获得10
21秒前
科研怪咖小白完成签到,获得积分10
21秒前
WQ发布了新的文献求助10
21秒前
21秒前
可爱的函函应助钙离子采纳,获得10
23秒前
人生发布了新的文献求助10
24秒前
25秒前
25秒前
乐乐应助初学者采纳,获得10
26秒前
彬琪完成签到,获得积分10
27秒前
2以李完成签到,获得积分10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975836
求助须知:如何正确求助?哪些是违规求助? 3520174
关于积分的说明 11201364
捐赠科研通 3256576
什么是DOI,文献DOI怎么找? 1798362
邀请新用户注册赠送积分活动 877539
科研通“疑难数据库(出版商)”最低求助积分说明 806426